|Phase III||Treatment||Closed||18 and over||NCI, Other||CDR0000069444|
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether giving cyclophosphamide together with doxorubicin is more effective than giving paclitaxel alone in treating breast cancer.
PURPOSE: This randomized phase III trial is studying cyclophosphamide and doxorubicin to see how well they work compared to paclitaxel in treating women with invasive breast cancer.
Further Study Information
- Compare the disease-free survival of women with operable breast cancer and 0-3 positive axillary lymph nodes treated with two different schedules (4 vs 6 courses) of adjuvant cyclophosphamide and doxorubicin vs paclitaxel. (Arms II and IV closed to accrual as of 1/30/2008)
- Compare the disease-free survival of patients treated with these regimens.
- Compare overall survival, local control, and time to distant metastasis in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Compare the effect of these regimens on the induction of menopause in premenopausal patients.
- Determine the discrepancy of myelosuppression in patients with MDR1 haplotypes on the CA treatment arm.
- Compare the disease-free survival of patients with MDR1 haplotypes treated with these regimens.
- Correlate CYP3A5, CYP2C8, and CYP2B6 polymorphisms with disease-free survival and toxicity in patients treated with these regimens.
OUTLINE: This is a randomized study. Patients are stratified according to menopausal status (premenopausal vs postmenopausal), estrogen receptor (ER)/progesterone receptor (PR) status (ER and/or PR positive or unknown vs ER and PR negative), and HER2/neu status (negative vs unknown vs positive [by immunohistochemistry 3+ staining or gene amplification by fluorescence in situ hybridization]). Patients are randomized to 1 of 4 treatment arms (arms II and IV closed to accrual as of 1/30/2008).
- Arm I: Patients receive doxorubicin IV and cyclophosphamide IV on day 1. Treatment repeats every 14 days for 4 courses.
- Arm II (closed to accrual as of 1/30/2008): Patients receive doxorubicin and cyclophosphamide as in arm I. Treatment repeats every 14 days for 6 courses.
- Arm III: Patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 14 days for 4 courses.
- Arm IV (closed to accrual as of 1/30/2008): Patients receive paclitaxel as in arm III. Treatment repeats every 14 days for 6 courses.
Treatment in all arms continues in the absence of disease progression or unacceptable toxicity.
Lumpectomy patients must then undergo radiotherapy. Mastectomy patients undergo radiotherapy at the discretion of the treating physician.
Patients are followed every 6 months for 2 years and then annually for 15 years.
PROJECTED ACCRUAL: A total of 4,646 patients will be accrued for this study within 29 months.
- Histologically confirmed invasive carcinoma of the breast with 0-3 positive axillary lymph nodes
- Meets 1 of the following criteria for node-negative disease:
- Negative sentinel lymph node biopsy
- At least 6 negative axillary lymph nodes removed and determined to be negative by axillary dissection
- Meets 1 of the following criteria for node-positive disease (1-3 positive axillary lymph nodes):
- At least 1 positive lymph node by sentinel lymph node biopsy AND at least 6 axillary lymph nodes removed by axillary dissection; of all the nodes removed from both the sentinel lymph node biopsy and the axillary dissection, 1-3 must be positive
- At least 6 lymph nodes removed by axillary dissection; 1-3 nodes from the axillary dissection must be positive
- "High-risk" disease that warrants chemotherapy (ultimately determined by the treating physician)
- Modified radical mastectomy or lumpectomy within the past 84 days required
- Negative tumor margins for invasive cancer and ductal carcinoma in situ (DCIS)
- Lobular carcinoma in situ (LCIS) at the margin allowed
- Multicentric disease allowed provided margins and axillary nodes are negative after resection
- Bilateral synchronous disease allowed
- Invasive cancer on one side and DCIS or LCIS on the contralateral side is allowed provided all other eligibility criteria are met
- No locally advanced, inflammatory, or metastatic breast cancer
- No dermal lymphatics involvement, even if there are no clinical signs of inflammatory cancer
- HER2/neu positive, negative, or unknown
- Hormone receptor status:
- Any estrogen and/or progesterone receptor status
- 18 and over
- Premenopausal or postmenopausal
- CTC 0-1
- Not specified
- Absolute neutrophil count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1.5 times upper limit of normal
- Creatinine no greater than 2.0 mg/dL
- No active congestive heart failure
- No myocardial infarction within the past 6 months
- Not pregnant or nursing
- Fertile patients must use effective nonhormonal contraception during and for at least 2 months after study participation
- No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
- No prior trastuzumab (Herceptin^®) for this malignancy
- See Disease Characteristics
- No prior chemotherapy for this malignancy
- No other concurrent chemotherapy
- No prior hormonal therapy for this malignancy except tamoxifen given for up to 4 weeks
- Prior tamoxifen or other selective estrogen receptor modulators (SERMs) for prevention or other indications (e.g., osteoporosis) allowed
- No concurrent exogenous hormonal therapy (including oral contraceptives, postmenopausal hormone replacement therapy, or raloxifene) except:
- Steroids for adrenal failure
- Hormonal agents for nondisease-related conditions (e.g., insulin for diabetes or synthroid for hypothyroidism)
- Intermittent dexamethasone as an antiemetic and premedication for paclitaxel
- No concurrent tamoxifen or other SERMs
- See Disease Characteristics
- No concurrent dexrazoxane
- No concurrent raloxifene
- Concurrent bisphosphonates for osteoporosis allowed
- Concurrent trastuzumab (Herceptin^®) allowed for patients with HER2-positive disease
- Concurrent enrollment on adjuvant bisphosphonate studies allowed
- Concurrent enrollment on adjuvant hormonal studies allowed provided hormonal therapy does not commence until completion of study chemotherapy
Trial Lead Organizations/Sponsors
Cancer and Leukemia Group BNational Cancer Institute
|Lawrence N. Shulman||Study Chair|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00041119
Information obtained from ClinicalTrials.gov on November 20, 2012
Back to Top